Effects of a proteasome inhibitor on the NF-κB signalling pathway in experimental osteoarthritis

Scand J Rheumatol. 2013;42(5):400-7. doi: 10.3109/03009742.2013.776101. Epub 2013 Jul 4.

Abstract

Objectives: To evaluate the effects of the proteasome inhibitor MG-132 on the expression of nuclear factor (NF)-κB p65, inhibitor (I)-κB, tumour necrosis factor (TNF)-α, and interleukin (IL)-1β in the cartilage and synovial tissues of rats with osteoarthritis (OA), and to investigate the role that the ubiquitin/proteasome system (UPS) plays in the OA process.

Method: A total of 144 adult male Sprague Dawley rats were randomly assigned to four groups: anterior cruciate ligament transaction (ACLT) + MG-132 (ACLT/M), ACLT + dimethylsulfoxide (ACLT/D), sham surgery (Sham), and naïve + MG-132 (naïve/M). Pathological morphology was undertaken. mRNA expression levels of NF-κB p65, I-κB, TNF-α, and IL-1β were determined using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). The activities of the 20S proteasome chymotrypsin-like and peptidylglutamyl-peptide hydrolase-like enzymes were measured using fluorospectrophotometry.

Results: The Mankin scores at all time points in ACLT/M rats were significantly lower than those in ACLT/D rats (p < 0.05). Despite the NF-κB p65 in the synovial tissue at 2 weeks after surgery and IL-1β in the cartilage tissue at 12 weeks after surgery, mRNA expression levels of NF-κB p65, IL-1β, and TNF-α at other time points in ACLT/M were significantly lower than those in ACLT/D (p < 0.05). mRNA levels of I-κB in the cartilage tissue in ACLT/M were significantly higher than those in ACLT/D at 2 weeks after surgery (p < 0.05). mRNA levels of I-κB in the synovial tissue in ACLT/M were higher than those in ACLT/D at all time points, and the difference was significant at 4 weeks after surgery (p < 0.05). MG-132 decreased the activities of the 20S proteasome chymotrypsin-like and peptidylglutamyl-peptide hydrolase-like enzymes in the cartilage and synovial tissues of rats.

Conclusions: The proteasome inhibitor MG-132 delays the progress of OA by alleviating synovial inflammation and protecting the articular cartilage tissue.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anterior Cruciate Ligament / surgery
  • Cartilage, Articular / drug effects
  • Cartilage, Articular / metabolism
  • Cartilage, Articular / pathology
  • Chymotrypsin / metabolism
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Disease Models, Animal
  • Endopeptidases / metabolism
  • I-kappa B Proteins / genetics
  • Interleukin-1beta / genetics
  • Leupeptins / pharmacology*
  • Male
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / genetics
  • Osteoarthritis / metabolism
  • Osteoarthritis / pathology
  • Physical Conditioning, Animal
  • Proteasome Endopeptidase Complex / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Signal Transduction / drug effects*
  • Synovial Membrane / drug effects
  • Synovial Membrane / metabolism
  • Synovial Membrane / pathology
  • Transcription Factor RelA / genetics
  • Transcription Factor RelA / metabolism*
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Cysteine Proteinase Inhibitors
  • I-kappa B Proteins
  • Interleukin-1beta
  • Leupeptins
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Endopeptidases
  • Chymotrypsin
  • Proteasome Endopeptidase Complex
  • peptidylglutamylpeptide hydrolase
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde